Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stock Report

Market Cap: US$54.5b

Alnylam Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ALNY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Oct 25SellUS$1,327,675Pushkal GargIndividual2,937US$457.64
02 Oct 25SellUS$1,103,451Kevin FitzgeraldIndividual2,441US$457.64
02 Oct 25SellUS$635,126Tolga TangulerIndividual1,405US$457.64
02 Oct 25SellUS$4,034,085Yvonne GreenstreetIndividual8,924US$457.64
02 Oct 25SellUS$1,727,284Jeffrey PoultonIndividual3,821US$457.64
18 Aug 25SellUS$632,759Kevin FitzgeraldIndividual1,396US$455.82
18 Aug 25SellUS$3,163,346Yvonne GreenstreetIndividual6,979US$455.82
18 Aug 25SellUS$1,030,727Jeffrey PoultonIndividual2,274US$455.82
18 Aug 25SellUS$632,759Tolga TangulerIndividual1,396US$455.82
18 Aug 25SellUS$632,759Pushkal GargIndividual1,396US$455.82
16 Apr 25SellUS$8,383Colleen ReitanIndividual36US$232.86
03 Mar 25SellUS$308,141Jeffrey PoultonIndividual1,264US$248.36
03 Mar 25SellUS$180,402Kevin FitzgeraldIndividual740US$248.36
03 Mar 25SellUS$189,183Pushkal GargIndividual776US$248.36
03 Mar 25SellUS$114,820Tolga TangulerIndividual471US$247.35
03 Mar 25SellUS$945,165Yvonne GreenstreetIndividual3,877US$248.36
28 Feb 25SellUS$119,878Kevin FitzgeraldIndividual496US$244.11
14 Feb 25SellUS$169,204Kevin FitzgeraldIndividual663US$264.87
14 Feb 25SellUS$398,325Pushkal GargIndividual1,561US$264.87
14 Feb 25SellUS$246,750Jeffrey PoultonIndividual967US$264.87
14 Feb 25SellUS$309,527Yvonne GreenstreetIndividual1,213US$264.87

Insider Trading Volume

Insider Buying: ALNY insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALNY?
Owner TypeNumber of SharesOwnership Percentage
State or Government56,1230.042%
Individual Insiders414,6140.31%
Public Companies1,392,3031.04%
Institutions131,732,02898.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 76.92% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.1%
Capital Research and Management Company
23,959,139US$9.9b-1.4%0.39%
12.4%
FMR LLC
16,316,965US$6.7b6.03%0.33%
10.3%
The Vanguard Group, Inc.
13,565,452US$5.6b2.02%0.07%
7.49%
BlackRock, Inc.
9,895,167US$4.1b-0.74%0.05%
3.05%
JP Morgan Asset Management
4,030,009US$1.7b112%0.15%
3.01%
T. Rowe Price Group, Inc.
3,974,278US$1.6b-46.5%0.13%
2.33%
State Street Global Advisors, Inc.
3,081,475US$1.3b-2.89%0.04%
2.11%
Baillie Gifford & Co.
2,789,356US$1.2b-8%0.52%
1.89%
Geode Capital Management, LLC
2,499,242US$1.0b4.19%0.06%
1.76%
Dodge & Cox
2,321,230US$957.8m-27.4%0.26%
1.54%
Norges Bank Investment Management
2,032,680US$838.7m0%0.05%
1.48%
Orbis Investment Management Limited
1,950,962US$805.0m-8.03%1.99%
1.38%
Wellington Management Group LLP
1,826,321US$753.6m-12%0.11%
1.24%
American Century Investment Management Inc
1,641,441US$677.3m-8.5%0.26%
1.05%
Regeneron Pharmaceuticals, Inc.
1,392,303US$574.5m-68.7%no data
1.03%
Arrowstreet Capital, Limited Partnership
1,355,609US$559.4m699%0.34%
1.03%
Invesco Ltd.
1,354,928US$559.1m12.8%0.14%
0.98%
Bank of America Corporation
1,288,338US$531.6m20.1%0.13%
0.91%
UBS Asset Management AG
1,196,768US$493.8m-20.3%0.04%
0.73%
Jane Street Group, LLC
958,750US$395.6m4,090%0.45%
0.68%
Two Sigma Advisers, LP
892,500US$368.3m235%0.72%
0.67%
Legal & General Investment Management Limited
887,780US$366.3m1.72%0.07%
0.63%
Northern Trust Global Investments
833,151US$343.8m0.17%0.04%
0.61%
Qube Research & Technologies Ltd
811,278US$334.8m0%0.49%
0.58%
Millennium Management LLC
770,565US$318.0m271%0.22%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/12 12:18
End of Day Share Price 2025/12/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 62 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Emily BodnarBerenberg
null nullBMO Capital Markets Equity Research